Healthcare Triangle, Inc. (HCTI): Nasdaq/NYSE listing notice — Healthcare Triangle receives Nasdaq bid price deficiency notice; stock below $1 for 30 days

Healthcare Triangle, Inc.

Closing bid price below $1.00 for 30 consecutive business days; 180-day cure period ends Aug 25, 2025.
Company may regain compliance by maintaining at least $1.00 closing bid for 10 consecutive days.
Previous deficiencies: stockholders' equity below $2.5M (since Mar 2024); annual meeting not yet held.
Nasdaq Hearings Panel granted conditional continued listing on Nov 4 & Dec 23, 2024; conditions not disclosed.
2024 Annual Meeting scheduled for Mar 28, 2025; proxy deadline for proposals is Mar 5, 2025.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Healthcare Triangle, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 26, 2025, Healthcare Triangle, Inc. (the “ Company ”) received written notice (the “ Bid Price Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that for the last 30 consecutive business days prior to the date of the Bid Price Notice, the closing bid price of the Company’s common stock was less than the $1.00 per share minimum bid price required for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Rule ”). In accordance with Nasdaq Listing

View on SEC.gov

Browse all listing & compliance notices →

Healthcare Triangle, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-017578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.